OXURION overview

Atlas Special Opportunities, LLC has converted 10 convertible bonds in Oxurion resulting in a EUR 250,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment [1] that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion. Leuven, BELGIUM – July 25, 2025 – 06:00 PM CET – In accordance with article 15 of the Belgian Act of May 2,...

Atlas Special Opportunities, LLC has converted 7 convertible bonds in Oxurion resulting in a EUR 175,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment [1] that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion. Leuven, BELGIUM – July 24, 2025 – 06:00 PM CET – In accordance with article 15 of the Belgian Act of May 2,...

Atlas Special Opportunities, LLC has converted 5 convertible bonds in Oxurion resulting in a EUR 125,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment [1] that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion. Leuven, BELGIUM – July 23, 2025 – 06:00 PM CET – In accordance with article 15 of the Belgian Act of May 2,...

Leuven, BELGIUM – July 23, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received a transparency notification as follows: Oxurion received a transparency notification on July 23, 2025, from Atlas Special Opportunities II, LLC indicating that as of July 21, 2025, it held 1,845,939 shares of the then outstanding 12,428,021 shares, and therefore crossed...

Leuven, BELGIUM – July 22, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received a transparency notification as follows: Oxurion received a transparency notification on July 18, 2025, from Atlas Special Opportunities II, LLC indicating that as of July 16, 2025, it held 2,460,942 shares of the then outstanding 12,428,021 shares, and therefore crossed...

This initiative is part of a long-term strategy for financial consolidation and growth support. Oxurion enters negotiations with Atlas Special Opportunities for a new €10 million convertible bond program, in €1 million tranches, convertible with a 10% premium over the 15-day volume-weighted average price (VWAP) The proceeds from the issuance are intended to be invested in Bitcoin and Ethereum Oxurion aims to leverage this long-term exposure to Bitcoin and Ethereum as an additional value...

Leuven, BELGIUM – July 17, 2025 at 8:30 AM CET, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, announces it has secured the financing for the acquisition of 72% of the share capital of Axiodis CRO, following a rigorous due diligence process and the fulfilment of all conditions precedent. The financing has been secured from Atlas Special Opportunities. Closing of the transaction is scheduled for August 1, 2025. The related dilution table is available on...